Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Competitive Advantages
Major Strategic Partnership: Tempest Therapeutics benefits significantly from a strategic collaboration with Roche/Genentech for its lead program, TPST-1120, providing substantial financial backing, clinical development resources, and external validation of its therapeutic approach.
Novel Mechanism of Action in Oncology: TPST-1120 targets the PPAR⍺ pathway, a distinct and differentiated mechanism in oncology that aims to reprogram the tumor microenvironment and enhance anti-tumor immunity, potentially overcoming resistance to existing therapies.
Diverse Clinical-Stage Pipeline: Beyond its lead asset, TPST boasts another clinical-stage program, TPST-1495 (EP2/EP4 antagonist), and preclinical assets, demonstrating a robust pipeline across multiple promising targets in oncology.
Risks
Clinical Trial Outcomes Risk: Their drug candidates may fail to demonstrate efficacy or safety in ongoing or future clinical trials, leading to program termination, significant delays, or failure to achieve regulatory approval.
Regulatory Approval Uncertainty: They may not obtain the necessary regulatory approvals from health authorities such as the FDA for their product candidates in a timely manner, or at all, due to various factors including trial results or regulatory requirements.
Funding and Liquidity Challenges: The company operates at a loss and requires substantial capital, facing the risk of insufficient funding to continue research, development, and commercialization efforts, which could necessitate further equity dilution or impact operations.
Over a week ago
Jun 26, 4:06 PM
Apr 22, 8:22 AM
Apr 2, 6:07 AM
Mar 30, 6:00 PM
Mar 11, 8:03 AM
Feb 25, 8:06 AM
Jan 22, 6:06 AM
Dec 9, 4:53 PM
Nov 25, 8:04 AM
Nov 19, 9:51 AM
Nov 19, 9:41 AM
Nov 19, 9:07 AM
Nov 5, 8:31 AM
Aug 11, 4:54 PM
No more stories
